Why the study?
Despite trials demonstrating the benefit of low-dose triple single pill combinations for hypertension, no such products are available for prescribers.
Does a low-dose triple single pill combination (telmisartan/amlodipine/indapamide) improve blood pressure control in patients with hypertension?
Comparison
GMRx2 vs placebo and each of the three possible dual combinations
Key result
The GMRx2 clinical development program is conducting two pivotal phase III trials to evaluate the efficacy and safety of a novel low-dose triple single pill combination for the treatment of hypertension.
Authors
Loading...
Ongoing GMRx2 trials may expand options if positive; leaves open confirmation of efficacy versus current hypertension therapies.
Does a low-dose triple single pill combination (telmisartan/amlodipine/indapamide) improve blood pressure control in patients with hypertension?
A novel low-dose triple single-pill combination of telmisartan, amlodipine, and indapamide is currently in pivotal trials to address the unmet need for early, effective hypertension management.
Rodgers et al. (2024) studied Hypertension. GMRx2 (telmisartan/amlodipine/indapamide) vs. Dual combinations (telmisartan/amlodipine, telmisartan/indapamide, amlodipine/indapamide) or Placebo was evaluated on Difference in change in home mean SBP from randomization to week 12 (ACT) or week 4 (PCT). The GMRx2 clinical development program is conducting two pivotal phase III trials to evaluate the efficacy and safety of a novel low-dose triple single pill combination for the treatment of hypertension.